No Data
No Data
No Data
No Data
No Data
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
cls.cnApr 15 14:37
These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Simply Wall StApr 11 18:36
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts
Across the recent three months, 6 analysts have shared their insights on Pacira BioSciences (NASDAQ:PCRX), expressing a variety of opinions spanning from bullish to bearish.The table below provides a
BenzingaApr 9 22:00
Needham: Reiterates Pacira BioSciences (PCRX.US) rating and adjusted from buy to buy rating, target price is $45.00.
Needham: Reiterates Pacira BioSciences (PCRX.US) rating and adjusted from buy to buy rating, target price is $45.00.
Zhitong FinanceApr 9 18:27
Needham Reiterates Buy on Pacira BioSciences, Maintains $45 Price Target
Needham analyst Serge Belanger reiterates Pacira BioSciences with a Buy and maintains $45 price target.
Analyst UpgradesApr 9 18:16
Aggressive Stock Portfolio: 13 Stocks Picked by Analysts
Yahoo FinanceApr 4 23:33
No Data
No Data